According to BioMarin Pharmaceutical's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 8.47544. At the end of 2022 the company had a P/S ratio of 7.83.
Year | P/S ratio | Change |
---|---|---|
2022 | 7.83 | -10.89% |
2021 | 8.79 | 2.68% |
2020 | 8.56 | -4.11% |
2019 | 8.92 | -12.33% |
2018 | 10.2 | -14.62% |
2017 | 11.9 | -6.55% |
2016 | 12.8 | -32.86% |
2015 | 19.0 | 5.87% |
2014 | 17.9 | -2.47% |
2013 | 18.4 | 48.85% |
2012 | 12.4 | 38.95% |
2011 | 8.90 | 12.36% |
2010 | 7.92 | 35.37% |
2009 | 5.85 | -2.4% |
2008 | 5.99 | -78.8% |
2007 | 28.3 | 58.38% |
2006 | 17.9 | -42.79% |
2005 | 31.2 | 41.13% |
2004 | 22.1 | -16.81% |
2003 | 26.6 | -2.43% |
2002 | 27.2 | -54.75% |
2001 | 60.2 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
![]() Sanofi SNY | 2.51 | -70.43% | ๐ซ๐ท France |
![]() Ultragenyx RARE | 7.37 | -13.03% | ๐บ๐ธ USA |
![]() Sangamo Therapeutics
SGMO | 3.10 | -63.47% | ๐บ๐ธ USA |
![]() Esperion Therapeutics ESPR | 1.60 | -81.09% | ๐บ๐ธ USA |
![]() Amicus Therapeutics
FOLD | 10.1 | 19.30% | ๐บ๐ธ USA |
![]() Catalyst Pharmaceuticals CPRX | 8.97 | 5.84% | ๐บ๐ธ USA |